These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
378 related items for PubMed ID: 1820342
1. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals. Wolf CR. IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342 [Abstract] [Full Text] [Related]
3. Characterization of the cytochrome P450 isozyme that metabolizes ochratoxin A, using metabolic inducers, inhibitors and antibodies. Hietanen E, Bartsch H, Béréziat JC, Castegnaro M, Michelon J. IARC Sci Publ; 1991; (115):297-304. PubMed ID: 1820345 [Abstract] [Full Text] [Related]
4. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. Nikolov IG, Chernozemsky IN, Idle JR. IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343 [Abstract] [Full Text] [Related]
5. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Smith CA, Moss JE, Gough AC, Spurr NK, Wolf CR. Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838 [Abstract] [Full Text] [Related]
6. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. Caporaso N. Ann Ist Super Sanita; 1991 Nov; 27(4):621-30. PubMed ID: 1820735 [Abstract] [Full Text] [Related]
8. Environmental and chemical carcinogenesis. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140 [Abstract] [Full Text] [Related]
9. Renal tumorigenicity of 1,1-dichloroethene in mice: the role of male-specific expression of cytochrome P450 2E1 in the renal bioactivation of 1,1-dichloroethene. Speerschneider P, Dekant W. Toxicol Appl Pharmacol; 1995 Jan; 130(1):48-56. PubMed ID: 7839370 [Abstract] [Full Text] [Related]
10. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341 [Abstract] [Full Text] [Related]
11. Sex- and strain-specific expression of cytochrome P450s in ochratoxin A-induced genotoxicity and carcinogenicity in rats. Pfohl-Leszkowicz A, Pinelli E, Bartsch H, Mohr U, Castegnaro M. Mol Carcinog; 1998 Oct; 23(2):76-85. PubMed ID: 9808161 [Abstract] [Full Text] [Related]
12. Modulation of the cytochrome P450 system as a mechanism of chemoprotection. Wolf CR, Mahmood A, Henderson CJ, McLeod R, Manson MM, Neal GE, Hayes JD. IARC Sci Publ; 1996 Oct; (139):165-73. PubMed ID: 8923029 [Abstract] [Full Text] [Related]
13. Concentrations of ochratoxin A in the urine of endemic nephropathy patients and controls in Bulgaria: lack of detection of 4-hydroxyochratoxin A. Castegnaro M, Maru V, Petkova-Bocharova T, Nikolov I, Bartsch H. IARC Sci Publ; 1991 Oct; (115):165-9. PubMed ID: 1820331 [Abstract] [Full Text] [Related]
14. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF, Liu JP, Chowbay B. Drug Metab Rev; 2009 Oct; 41(2):89-295. PubMed ID: 19514967 [Abstract] [Full Text] [Related]